VEGF News and Research RSS Feed - VEGF News and Research

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.
RCC renal function independent of axitinib-induced proteinuria

RCC renal function independent of axitinib-induced proteinuria

Treatment with the vascular endothelial growth factor receptor inhibitor axitinib does not adversely affect renal function in patients with metastatic renal cell carcinoma even in the presence of proteinuria, a Japanese study indicates. [More]
Lilly receives FDA approval for CYRAMZA (ramucirumab)

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). [More]
Exudation-free period key to cataract surgery success in AMD

Exudation-free period key to cataract surgery success in AMD

Cataract surgery can benefit patients with exudative age-related macular degeneration previously treated with anti-vascular endothelial growth factors if they have been treated and are exudation-free for more than 12 months, study findings indicate. [More]
Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed a $33M private placement of its Series C Preferred Stock. [More]
Success for nurse practitioner-delivered intravitreal injection service for wAMD

Success for nurse practitioner-delivered intravitreal injection service for wAMD

Well-trained nurse practitioners can successfully provide an injection service for the treatment of wet age-related macular degeneration with ranibizumab, an audit shows. [More]

DEX implant improves visual acuity in patients with diabetic macular oedema

Patients with diabetic macular oedema benefit from intravitreal dexamethasone implants, a study shows, with the treatment improving best-corrected visual acuity with an acceptable safety profile. [More]
VE-PTP potential treatment target for retinal and choroidal vascular diseases

VE-PTP potential treatment target for retinal and choroidal vascular diseases

Targeting vascular endothelial-protein tyrosine phosphatase, which negatively regulates TIE2 activation, could help to stabilise retinal and choroidal blood vessels, researchers report. [More]
Eylea receives Health Canada approval for treatment of CRVO and DME

Eylea receives Health Canada approval for treatment of CRVO and DME

Bayer Inc. announced today that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of diabetic macular edema (DME). This new indication comes just six weeks following the October 16th approval of Eylea for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). [More]
Research: HD-IL2 can be effective in mRCC patients pre-treated with VEGF-targeted agents

Research: HD-IL2 can be effective in mRCC patients pre-treated with VEGF-targeted agents

High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland. [More]
Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals. [More]
3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. [More]

VEGF-B can regenerate damaged peripheral nerves without causing growth of new blood vessels

Researchers at the University of Illinois at Chicago College of Medicine have found that a growth factor can regenerate damaged peripheral nerves without causing the growth of new blood vessels -- making it a unique candidate to treat nerve damage in areas of the body where the proliferation of blood vessels would be a drawback. [More]
University of Leeds researchers make new synthetic anti-cancer molecule

University of Leeds researchers make new synthetic anti-cancer molecule

Researchers at the University of Leeds have made a new synthetic anti-cancer molecule that targets two key mechanisms in the spread of malignant tumours through the body. [More]
Bevacizumab–erlotinib combined efficacy may depend on VEGF level

Bevacizumab–erlotinib combined efficacy may depend on VEGF level

Bevacizumab may enhance the antitumour activity of erlotinib by increasing the intratumoural concentration of erlotinib in some non-small-cell lung cancers expressing high levels of vascular endothelial growth factor, Japanese researchers report. [More]
Endothelin gene expression linked to vision loss in premature babies

Endothelin gene expression linked to vision loss in premature babies

A gene known to play a major role in constricting blood vessels also appears to be a major player in the aberrant blood vessel growth that can destroy the vision of premature babies. [More]
New treatment could halt growth of tumours in prostate cancer patients

New treatment could halt growth of tumours in prostate cancer patients

Scientists believe a new treatment, shown to be effective in mice, could halt the growth of tumours in patients with prostate cancer. [More]
Scientists may have discovered new way to repair damaged tissue

Scientists may have discovered new way to repair damaged tissue

By transforming human scar cells into blood vessel cells, scientists at Houston Methodist may have discovered a new way to repair damaged tissue. The method, described in an upcoming issue of Circulation (early online), appeared to improve blood flow, oxygenation, and nutrition to areas in need. [More]
FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. [More]
Preeclampsia study provides pathways for new therapeutic treatments

Preeclampsia study provides pathways for new therapeutic treatments

A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause of maternal and infant death worldwide, a discovery that could lead to the development of new therapeutic treatments. [More]
Researchers reveal how particular melanoma cells help tumors resist drugs

Researchers reveal how particular melanoma cells help tumors resist drugs

UNC School of Medicine researchers have pinpointed a set of intriguing characteristics in a previously unknown subpopulation of melanoma cancer cells in blood vessels of tumors. These cells, which mimic non-cancerous endothelial cells that normally populate blood vessels in tumors, could provide researchers with another target for cancer therapies. [More]